Literature DB >> 20869467

Guillain-Barré syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009.

Nizar Souayah1, P A Michas-Martin, Abu Nasar, Nataliya Krivitskaya, Hussam A Yacoub, Hafiz Khan, Adnan I Qureshi.   

Abstract

Using data from Vaccine Adverse Event Reporting System, we identified 69 reports of Guillain-Barré Syndrome (GBS) after Gardasil vaccination that occurred in the United States between 2006 and 2009. The onset of symptoms was within 6 weeks after vaccination in 70% of the patients in whom the date of vaccination was known. The estimated weekly reporting rate of post-Gardasil GBS within the first 6 weeks (6.6 per 10,000,000) was higher than that of the general population, and higher than post-Menactra and post-influenza vaccinations. Further prospective active surveillance for accurate ascertainment and identification of high-risk groups of GBS after Gardasil vaccination is warranted. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20869467     DOI: 10.1016/j.vaccine.2010.09.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.

Authors:  Rohit P Ojha; Bradford E Jackson; Joseph E Tota; Tabatha N Offutt-Powell; Karan P Singh; Sejong Bae
Journal:  Hum Vaccin Immunother       Date:  2013-09-06       Impact factor: 3.452

Review 2.  Human papillomavirus vaccination: a case study in translational science.

Authors:  Allyson K Palmer; Antoneicka L Harris; Robert M Jacobson
Journal:  Clin Transl Sci       Date:  2014-05-19       Impact factor: 4.689

3.  Vaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018.

Authors:  G Gross; N Becker; N H Brockmeyer; S Esser; U Freitag; M Gebhardt; L Gissmann; P Hillemanns; H Grundhewer; H Ikenberg; H Jessen; A Kaufmann; S Klug; J P Klußmann; A Nast; D Pathirana; K U Petry; H Pfister; U Röllinghof; P Schneede; A Schneider; E Selka; S Singer; S Smola; B Sporbeck; M von Knebel Doeberitz; P Wutzler
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-03       Impact factor: 2.915

Review 4.  Safety of Human Papillomavirus Vaccines: An Updated Review.

Authors:  Anastasia Phillips; Cyra Patel; Alexis Pillsbury; Julia Brotherton; Kristine Macartney
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

5.  Evaluation of optic neuritis following human papillomavirus vaccination.

Authors:  Gayathri Sridhar; Fang Tian; Richard Forshee; Martin Kulldorff; Nandini Selvam; Andrea Sutherland; Wilson Bryan; Samuel Barone; Lei Xu; Hector S Izurieta
Journal:  Hum Vaccin Immunother       Date:  2017-05-02       Impact factor: 3.452

Review 6.  Safety of human papillomavirus vaccines: a review.

Authors:  Kristine K Macartney; Clayton Chiu; Melina Georgousakis; Julia M L Brotherton
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

Review 7.  A review of clinical trials of human papillomavirus prophylactic vaccines.

Authors:  John T Schiller; Xavier Castellsagué; Suzanne M Garland
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

8.  Understanding the approach of family physicians in Turkey to the problem of vaccine rejection.

Authors:  Ayşegül Erdoğan; Kutay Güven; Ahmet Rıza Şahin; Ramazan Azim Okyay
Journal:  Hum Vaccin Immunother       Date:  2021-02-19       Impact factor: 3.452

9.  Human papillomavirus vaccine and systemic lupus erythematosus.

Authors:  Mariele Gatto; Nancy Agmon-Levin; Alessandra Soriano; Raffaele Manna; Ramit Maoz-Segal; Shaye Kivity; Andrea Doria; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2013-04-28       Impact factor: 3.650

10.  HPV vaccines and cancer prevention, science versus activism.

Authors:  Lucija Tomljenovic; Judy Wilyman; Eva Vanamee; Toni Bark; Christopher A Shaw
Journal:  Infect Agent Cancer       Date:  2013-02-01       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.